High plasma GFAP level predicts disability accumulation in secondary progressive MSSeptember 14, 2020Multiple Sclerosis
Exposure to DMT may delay disability accumulation in primary progressive MSSeptember 11, 2020Multiple Sclerosis
In MS, serious adverse effects are more common in rituximab versus ocrelizumabSeptember 11, 2020Multiple Sclerosis
Smoking increases risk of high plasma NfL levels in patients with MSSeptember 11, 2020Multiple Sclerosis
Lowering rituximab dose in patients with MS proves safe and effectiveSeptember 9, 2020Multiple Sclerosis
Efficacy of disease-modifying therapies in treatment-naïve patients with MSSeptember 3, 2020Multiple Sclerosis
Personalized extended interval dosing does not reduce efficacy of natalizumab in MSSeptember 3, 2020Multiple Sclerosis
